Macao SAR’s First Authorization of a Phase III Clinical Trial for an Innovative Traditional Chinese Medicine Drug Not Yet Marketed in the Chinese Mainland: Regulatory Comparison and Practical Implications

WANG Dan, LI Peng-bin, ZHAO Jun-ning

China Food Drug Administration ›› 2026, Vol. 0 ›› Issue (10) : 4-17.

PDF(2721 KB)
PDF(2721 KB)
China Food Drug Administration ›› 2026, Vol. 0 ›› Issue (10) : 4-17. DOI: 10.3969/j.issn.1673-5390.2026.10.001
Special Report

Macao SAR’s First Authorization of a Phase III Clinical Trial for an Innovative Traditional Chinese Medicine Drug Not Yet Marketed in the Chinese Mainland: Regulatory Comparison and Practical Implications

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 0(10): 4-17 https://doi.org/10.3969/j.issn.1673-5390.2026.10.001

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2721 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © China Food Drug Administration, All Rights Reserved.
Tel: 010-83025781　
Powered by Beijing Magtech Co. Ltd,.

/

〈 〉